Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(2):96–102. doi: 10.1002/clc.4960230206

Effects of early captopril therapy after myocardial infarction on the incidence of late potentials

John A Chiladakis 1, George Karapanos 1, George Agelopoulos 1, Dimitris Alexopoulos 1, Antonis S Manolis 1,✉
PMCID: PMC6654829  PMID: 10676600

Abstract

Background: Late potentials (LP) on signal‐averaged electrocardiography (SAECG), recorded 6 to 30 days after an acute myocardial infarction (AMI), identify patients at risk for late arrhythmic events. Angiotensin‐converting enzyme (ACE) inhibitors have been shown to reduce ventricular remodeling and cardiovascular mortality after AMI.

Hypothesis: The aim of this study was to investigate the effect of early (< 24 h) administration of captopril on the presence of LP on Days 6–30 after AMI.

Methods: The study included 117 patients with a first AMI; 63 patients (53 men and 10 women, aged 59±12 years), 35 with an anterior and 28 with an inferior AMI (44 thrombolyzed), received early captopril therapy. The control group consisted of 54 age‐matched patients (39 men and 15 women, aged 60 ± 12 years), 19 with an anterior and 35 with an inferior AMI (31 thrombolyzed, p = NS), who did not receive early therapy with an ACE inhibitor. The mean left ventricular ejection fraction was similar in both groups (48 vs. 46%). Time domain analysis of SAECG was performed using a band‐pass filter of 40–250 Hz. Late potentials were considered present if any two of three criteria were met: (1) Filtered QRS duration (QRSD) > 114 ms, (2) root‐mean‐square voltage of the last 40 ms of the QRS complex (RMS) > 20 m̈V, and (3) duration of low amplitude (< 40 m̈V) signal of the terminal portion of the QRS (LAS) > 38 ms.

Results: In the two groups of patients there were no differences in mean values of SAECG parameters. No patient was receiving any antiarrhythmic drugs. In the captopril group LPs were present in 9 of 63 patients (14%) and in the control group in 17 of 54 patients (31 %) (p =0.046). There was no difference in the number of patients with a patent infarct‐related artery in the two groups (76 vs. 59%).

Conclusion: Captopril treatment early after an AMI reduces the incidence of LPs recorded on Days 6–30 and may thus favorably affect the arrhythmogenic substrate.

Keywords: late potentials, signal‐averaged electrocardiogram, captopril, arrhythmias, angiotensin‐converting enzyme inhibitors

Full Text

The Full Text of this article is available as a PDF (722.8 KB).

Reference

  • 1. The SOLVD Investigators : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691 [DOI] [PubMed] [Google Scholar]
  • 2. Pfeffer M, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rutherford J, Wertheimer JH, Hawkins CM: The SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–677 [DOI] [PubMed] [Google Scholar]
  • 3. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico : GISSI‐3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6‐week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–1122 [PubMed] [Google Scholar]
  • 4. ISIS Collaborative Group : ISIS‐4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685 [PubMed] [Google Scholar]
  • 5. Kingma JH, van Gilst WH, Peels CH, Dambrink JHE, Verheugt FWA, Wielenga RP: Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: Results from the Captopril and Thrombolysis study (CATS). Eur Heart J 1994; 15: 898–907 [DOI] [PubMed] [Google Scholar]
  • 6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828 [PubMed] [Google Scholar]
  • 7. Koeber L, Torp Pedersen C, Carlsen JA, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole D, Auglert L, Pavly NC, Alliot E, Person S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group : A clinical trial of the angiotensin‐converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1676 [DOI] [PubMed] [Google Scholar]
  • 8. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman B, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabeti R, Haakenson C: A comparison of enalapril with hydralazineisosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–310 [DOI] [PubMed] [Google Scholar]
  • 9. Ertl G, Kloner RA, Alexander RA, Braunwald E: Limitation of experimental infarct size by an angiotensin‐converting enzyme inhibitor. Circulation 1982; 65: 40–48 [DOI] [PubMed] [Google Scholar]
  • 10. Ambrosini E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long‐term Evaluation (SMILE) Study Investigators : The effect of the angiotensin‐converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–85 [DOI] [PubMed] [Google Scholar]
  • 11. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, for the CONSENSUS II Study Group : Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992; 327: 678–684 [DOI] [PubMed] [Google Scholar]
  • 12. Kloner RA, Przyklenk K: Cardioprotection with angiotensin‐converting enzyme inhibitors: Redefined for the 1990s. Clin Cardiol 1992; 15: 95–103 [DOI] [PubMed] [Google Scholar]
  • 13. Denniss AR, Ross DL, Richards DA, Uther JB: Changes in ventricular activation time on the signal‐averaged‐electrocardiogram in the first year after acute myocardial infarction. Am J Cardiol 1987; 60: 580–583 [DOI] [PubMed] [Google Scholar]
  • 14. Kuchar DL, Thorburn CW, Sammel NL: Prediction of serious arrhythmic events after myocardial infarction: Signal‐averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987; 9: 531–538 [DOI] [PubMed] [Google Scholar]
  • 15. Grimm M, Billhart RA, Mayerhofer KE, Denes P: Prognostic significance of signal‐averaged ECGs during acute myocardial infarction: A preliminary report. J Electrophysiol 1988; 21: 283–288 [DOI] [PubMed] [Google Scholar]
  • 16. Lewis SJ, Lander PT, Taylor PA, Chamberlain DA, Vincent R: Evolution of late potential activity in the first six weeks after acute myocardial infarction. Am J Cardiol 1989; 63: 647–651 [DOI] [PubMed] [Google Scholar]
  • 17. El Sherif N, Ursell SN, Bekheit S, Fontaine J, Turitto G, Henkin R, Caref EB: Prognostic significance of the signal‐averaged ECG depends on the time of recording in the postinfarction period. Am Heart J 1989; 118: 256–264 [DOI] [PubMed] [Google Scholar]
  • 18. Junker A, Ahlquist P, Thayssen P, Angelo Nielsen K, Mickley H, Moeller M: Ventricular late potentials after early enalapril treatment in acute myocardial infarction. Am J Cardiol 1995; 76: 1300–1302 [DOI] [PubMed] [Google Scholar]
  • 19. Greenberg H, Gillespie J, Dwyer EM, and the Multicenter Post‐Infarction Research Group : A new electrocardiographic classification for post‐myocardial infarction clinical trials. Am J Cardiol 1987; 59: 1057–1063 [DOI] [PubMed] [Google Scholar]
  • 20. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Grugesell H, Reicheck N, Sahn D, Schnittger I, Silverman NH, Tajik J: Recommendations for quantitation of the left ventricle by two‐dimensional echocardiography. J Am Soc Echo 1989; 2: 358–367 [DOI] [PubMed] [Google Scholar]
  • 21. Chesebro JH, Knatterud G, Roberts R, Boger J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987; 76: 142–154 [DOI] [PubMed] [Google Scholar]
  • 22. Breithardt G, Cain ME, El Sherif N, Flowers N, Hombach V, Janse M, Simson MB, Steinbeck G: Standards for analysis of ventricular late potentials using high resolution or signal‐averaged electrocardiography. Circulation 1991; 83: 1481–1486 [DOI] [PubMed] [Google Scholar]
  • 23. van Gilst WH, de Graeff PA, Wesseling H, de Langen CDJ: Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol 1986; 8: 722–728 [PubMed] [Google Scholar]
  • 24. Raya TE, Gay RG, Aguirre M, Goldman S: Importance of venodilatation in prevention of left ventricular dialatation after chronic large myocardial infarction in rats: A comparison of captopril and hydralazine. Circ Res 1989; 64: 330–337 [DOI] [PubMed] [Google Scholar]
  • 25. Oldroyd KG, Pye MP, Ray SG, Christie J, Ford I, Cobbe SM, Dargie HJ: Effects of early captopril administration on infarct expansion, left ventricular remodelling and exercise capacity after AMI. Am J Cardiol 1991; 68: 713–718 [DOI] [PubMed] [Google Scholar]
  • 26. Sogaard P, Gotzsche CO, Ravkilde J, Norgaard A, Thygesen K: Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril. Circulation 1994; 90: 101–107 [DOI] [PubMed] [Google Scholar]
  • 27. Budaj A, Cybulski J, Cedro K, Karczmarewicz S, Maciejewicz J, Wisniewski M, Ceremuzynski L: Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Eur Heart J 1996; 17: 1506–1510 [DOI] [PubMed] [Google Scholar]
  • 28. Hemsworth PD, Pallandi RT, Campbell TJ: Cardiac electrophysiological actions of captopril: Lack of direct antiarrhythmic effects. Br J Pharmacol 1989; 98: 192–196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Gang ES, Lew AS, Hong M, Wang FZ, Siebert CA, Peter T: Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 1989; 321: 712–716 [DOI] [PubMed] [Google Scholar]
  • 30. Lange RA, Cigarroa RG, Wells PJ, Kremers MS, Hillis LD: Influence of anterograde flow in the infarct artery on the incidence of late potentials after acute myocardial infarction. Am J Cardiol 1990; 65: 554–558 [DOI] [PubMed] [Google Scholar]
  • 31. Denes P, El Sherif N, Katz R, Capone R, Carlson M, Mitchell B, Ledingham R, for the Cardiac Arrhythmia Suppression Trial (CAST) SAECG substudy investigators : Prognostic significance of signal‐averaged electrocardiogram after thrombolytic therapy and/or angioplasty during acute myocardial infarction (CAST substudy). Am J Cardiol 1994; 74: 216–220 [DOI] [PubMed] [Google Scholar]
  • 32. Zaman AG, Morris JL, Smyllie JH, Cowan JC: Late potentials and ventricular enlargement after myocardial infarction. A new role for high‐resolution electrocardiography? Circulation 1993; 88: 905–914 [DOI] [PubMed] [Google Scholar]
  • 33. Bonarjee VVS, Carstensen S, Caidahl K, Nilsen DWI, Edner M, Berning J, on behalf of the CONSENSUS II multi‐echo study group : Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cardiol 1993; 72: 1004–1009 [DOI] [PubMed] [Google Scholar]
  • 34. Sogaard P, Gotzsche CO, Ravkilde J, Thygesen K: Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction. Circulation 1993; 87: 1093–1099 [DOI] [PubMed] [Google Scholar]
  • 35. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, Manapace FJ, Parker JO, Lewis S, Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E, for the SAVE Investigators : Quantitative two‐dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: The protective effects of captopril. Circulation 1994; 89: 68–75 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES